[Appropriate use of anti-methicillin-resistant Staphylococcus aureus agents in a retrospective study].
The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6% of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4% of the cases examined. On the other hand, TDM was also conducted in 60% of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.
Nakamura
Yasutaka
Y
Division of Pharmacy, Chiba University Hospital, Chiba, Japan. nakay@ho.chiba-u.ac.jp
Yokoyama
Iichirou
I
Hashimoto
Noriko
N
Hasegawa
Atsushi
A
Nakasa
Hiromitsu
H
Nakamura
Hiroyoshi
H
Watanabe
Masaharu
M
Nomura
Fumio
F
Watanabe
Akira
A
Igari
Hidetoshi
H
Sato
Takeyuki
T
Nakazawa
Kazuyoshi
K
Ariyoshi
Noritaka
N
Kitada
Mitsukazu
M
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D016903:Drug Monitoring; D024881:Drug Resistance, Bacterial; D006801:Humans; D016106:Methicillin Resistance; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D017334:Teicoplanin / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors; D014640:Vancomycin / Q000008:administration & dosage* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D003982:Dibekacin; D017334:Teicoplanin; D014640:Vancomycin; C031986:arbekacin